These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 2053292)
1. Inhibition of duck hepatitis B virus infection by lysosomotropic agents. Offensperger WB; Offensperger S; Walter E; Blum HE; Gerok W Virology; 1991 Jul; 183(1):415-8. PubMed ID: 2053292 [TBL] [Abstract][Full Text] [Related]
2. Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. Civitico G; Wang YY; Luscombe C; Bishop N; Tachedjian G; Gust I; Locarnini S J Med Virol; 1990 Jun; 31(2):90-7. PubMed ID: 1696959 [TBL] [Abstract][Full Text] [Related]
3. Antiviral effects of PNA in duck hepatitis B virus infection model. Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953 [TBL] [Abstract][Full Text] [Related]
4. Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model. Bishop N; Civitico G; Wang YY; Guo KJ; Birch C; Gust I; Locarnini S J Med Virol; 1990 Jun; 31(2):82-9. PubMed ID: 2388048 [TBL] [Abstract][Full Text] [Related]
5. Sulfated polyanions do not inhibit duck hepatitis B virus infection. Offensperger WB; Offensperger S; Walter E; Blum HE; Gerok W Antimicrob Agents Chemother; 1991 Nov; 35(11):2431-3. PubMed ID: 1804020 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. Hafkemeyer P; Keppler-Hafkemeyer A; al Haya MA; von Janta-Lipinski M; Matthes E; Lehmann C; Offensperger WB; Offensperger S; Gerok W; Blum HE Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615 [TBL] [Abstract][Full Text] [Related]
7. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Heijtink RA; De Wilde GA; Kruining J; Berk L; Balzarini J; De Clercq E; Holy A; Schalm SW Antiviral Res; 1993 Jun; 21(2):141-53. PubMed ID: 8338351 [TBL] [Abstract][Full Text] [Related]
9. Duck hepatitis B virus infection of hepatocytes is not dependent on low pH. Rigg RJ; Schaller H J Virol; 1992 May; 66(5):2829-36. PubMed ID: 1560528 [TBL] [Abstract][Full Text] [Related]
10. Duck hepatitis B virus infection of Muscovy duck hepatocytes and nature of virus resistance in vivo. Pugh JC; Simmons H J Virol; 1994 Apr; 68(4):2487-94. PubMed ID: 7511172 [TBL] [Abstract][Full Text] [Related]
11. The carbocyclic analog of 2'-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. Fourel I; Saputelli J; Schaffer P; Mason WS J Virol; 1994 Feb; 68(2):1059-65. PubMed ID: 8289335 [TBL] [Abstract][Full Text] [Related]
12. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Noordeen F; Vaillant A; Jilbert AR Antimicrob Agents Chemother; 2013 Nov; 57(11):5299-306. PubMed ID: 23939904 [TBL] [Abstract][Full Text] [Related]
13. Uptake of duck hepatitis B virus into hepatocytes occurs by endocytosis but does not require passage of the virus through an acidic intracellular compartment. Köck J; Borst EM; Schlicht HJ J Virol; 1996 Sep; 70(9):5827-31. PubMed ID: 8709200 [TBL] [Abstract][Full Text] [Related]
14. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo. Offensperger WB; Offensperger S; Keppler-Hafkemeyer A; Hafkemeyer P; Blum HE Antivir Ther; 1996 Aug; 1(3):141-6. PubMed ID: 11322247 [TBL] [Abstract][Full Text] [Related]
15. Duck hepatitis B virus model for screening of antiviral agents from medicinal herbs. Mi Z; Chen H; Zhang X; Shao X; Li Z; Wu X Chin Med J (Engl); 1995 Sep; 108(9):660-4. PubMed ID: 8575230 [TBL] [Abstract][Full Text] [Related]
16. Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Yokota T; Konno K; Chonan E; Mochizuki S; Kojima K; Shigeta S; de Clercq E Antimicrob Agents Chemother; 1990 Jul; 34(7):1326-30. PubMed ID: 2201250 [TBL] [Abstract][Full Text] [Related]
17. [Inhibition of binding peptides on replication of duck hepatitis B virus]. Jia HY; Chen Z; Zhou LF; Chen F; Zhu HH; Liu JH; Xu XY Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 34(2):116-20. PubMed ID: 15812883 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro. Schröder I; Holmgren B; Oberg M; Löfgren B Antiviral Res; 1998 Jan; 37(1):57-66. PubMed ID: 9497073 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of duck hepatitis B virus infection of liver cells by combined treatment with viral e antigen and carbohydrates. Maenz C; Loscher C; Iwanski A; Bruns M J Gen Virol; 2008 Dec; 89(Pt 12):3016-3026. PubMed ID: 19008388 [TBL] [Abstract][Full Text] [Related]